MANCHESTER, England--(BUSINESS WIRE)--Manchester-based Synexus, a global leader in the recruitment of patients to its own research centres, recruited 2,200 of the 17,802 patients who took part in the recent JUPITER trial presented on Monday 30th March at the ACC*and published in the Lancet. It was the most successful source of patient recruitment providing 13% of participants to just 1% of the 1315 sites taking part in the study.

Commenting on Synexus role in the JUPITER trial, Michael Fort, CEO said: “Our success in recruiting patients quickly and efficiently is increasingly well known across a range of therapies. With JUPITER we have also been able to demonstrate, very clearly, just how cost effective our methods are, in particular slashing monitoring costs. Of the 2,200 patients we enrolled only two failed to complete the study and that’s another achievement in terms of the quality of patients we are able to deliver for our clients.”

- ends -

*ACC The American College of Cardiology

Synexus® background

Synexus® headquartered in Manchester, England, is the world’s largest multi-national company dedicated to the recruitment of clinical trials at its own research centres across the globe on behalf of its pharmaceutical, biotech and CRO clients. Synexus has 16 research centres across the UK, Poland, Hungary, Bulgaria, India and South Africa staffed by full time GCP trained investigators. Synexus® currently has more than twelve thousand patients enrolled in clinical trials. For more information go to www.synexus.com.